

Title:

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Authors and Affiliations:

Cong Liu^{1, 2}, Milena Sch6nke^{1, 2}, Borah Spoorenberg^{1, 2}, Joost M. Lambooi^{3, 4}, Hendrik J.P. van der Zande³, Enchen Zhou^{1, 2}, Maarten E. Tushuizen⁵, Anne-Christine Andr6asson⁶, Andrew Park⁷, Stephanie Oldham⁸, Martin Uhrbom⁶, Ingela Ahlstedt⁶, Yasuhiro Ikeda⁷, Kristina Wallenius⁶, Xiao-Rong Peng⁶, Bruno Guigas³, Mari6tte R. Boon^{1, 2}, Yanan Wang^{9, *}, Patrick C.N. Rensen^{1, 2, 9, *}

¹Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands. ²Eindhoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands. ³Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. ⁴Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. ⁵Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands. ⁶Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ⁷Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, USA. ⁸Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. ⁹Med-X institute, Center for Immunological and Metabolic Diseases, and Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China.

*Corresponding authors

27 **Contact information of corresponding authors:**

28 Yanan Wang, PhD

29 Address: Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong

30 University, 277 West Yanta Road, Xi'an, Shaanxi, China

31 Phone number: +86-29-85323338

32 E-mail: y_wang@xjtufh.edu.cn

33

34 Patrick C.N. Rensen, PhD

35 Address: Department of Medicine, Division of Endocrinology, Leiden University Medical

36 Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

37 Phone number: +31-(0)71-52-63078

38 E-mail: p.c.n.rensen@lumc.nl

Abstract

Analogues of the hepatokine FGF21 are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis.

Keywords: fibroblast growth factor 21; steatohepatitis; lipid/scar-associated macrophages; liver-adipose tissue crosstalk

62 **Grant support:**

63 This work was supported by the Dutch Diabetes Research Foundation (2015.81.1808 to
64 M.R.B.); Netherlands Organisation for Scientific Research-NWO (VENI grant 91617027 to
65 Y.W.); Chinese Scholarship Council grants (CSC 201606010321 to E.Z.); the Novo Nordisk
66 Foundation (NNF18OC0032394 to M.S.); and the Netherlands Cardiovascular Research
67 Initiative: an initiative with support of the Dutch Heart Foundation (CVON-GENIUS-2 to
68 P.C.N.R.).

Introduction

The liver is the nexus of many metabolic pathways, including those of glucose, fatty acids (FAs) and cholesterol. In health, these metabolites are distributed to peripheral tissues while preventing long-lasting accumulation in the liver. In a pathological state, however, lipids may accrue in the liver, thereby impairing liver function and carving the path towards the development of nonalcoholic fatty liver disease (NAFLD) (1). NAFLD is considered a spectrum of liver diseases ranging from liver steatosis, characterized by lipid accumulation in hepatocytes, to nonalcoholic steatohepatitis (NASH) with hepatic steatosis, lobular inflammation, hepatocyte ballooning and varying degrees of fibrosis (2, 3). Patients diagnosed with NASH are predisposed to developing cirrhosis and hepatocellular carcinoma, among whom patients with severe liver fibrosis are at greatest risk of overall- and liver-related mortality (4). Despite this, there are currently no approved pharmaceutical therapeutics for NASH. Instead, lifestyle modifications remain the first-line treatment for NASH, although this is rarely attainable in the long term, and liver transplantation is still the sole intervention to treat the end-stage of NASH (2, 5). Thus, there is an unmet need for therapeutic strategies that control the progression of NASH, in particular of liver fibrosis, and reverse the underlying pathophysiology.

Current hypotheses suggest that adipose tissue dysfunction and lipid spillover leads to hepatic lipotoxicity, and thereby the initiation of NASH (6, 7), which further progresses through the inflammatory response triggered by hepatic lipotoxicity (7). This inflammatory response and subsequent fibrogenesis are primarily initiated by liver macrophages (8). Hepatic macrophages mainly consist of embryonically-derived macrophages, termed resident Kupffer cells (ResKCs), and monocyte-derived macrophages (MoDMacs) that are recruited from the circulation (9). In the steady state, ResKCs serve as sentinels for liver homeostasis. In NASH, liver injury caused by excess lipids and hepatocyte damage/death,

triggers ResKC activation, leading to pro-inflammatory cytokine and chemokine release (10). This fosters the infiltration of newly-recruited monocytes into the liver, which gives rise to various pro-inflammatory and pro-fibrotic macrophage subsets (8, 10). Interestingly, recent preclinical and clinical studies have reported that modulation of ResKC activation, monocyte recruitment or macrophage differentiation, to some extent, can attenuate NASH (8, 11). In light of these findings, FGF21, a hepatokine with both lipid-lowering and anti-inflammatory properties (12, 13), has been brought to the foreground as a promising potential therapeutic to treat NASH.

The specificity of FGF21 action for various metabolic tissues is determined by the FGF receptor (FGFR) which forms a heterodimer with the transmembrane co-receptor β -Klotho (KLB) (14, 15). While the FGFR is ubiquitously expressed, KLB is primarily expressed in the liver and adipose tissue (14, 15), therefore possibly limiting FGF21 action to these tissues. Physiologically, FGF21 is considered a stress-induced hormone whose levels rise in metabolically compromised states, such as obesity (16) and NASH (17). The increased FGF21 in these pathologies is likely induced by an accumulation of lipids in the liver (18). As such, plasma FGF21 also positively correlates with the severity of steatohepatitis and fibrosis in patients with NASH (17). Induction of FGF21 is thought to mediate a compensatory response to limit metabolic dysregulation (19), although this level is not sufficient. Interestingly, two phase 2a clinical trials reported that pharmacological FGF21 treatment improves liver steatosis in NASH patients (20, 21). While an *in vivo* study testing the therapeutic potency of FGF21 in choline-deficient and high-fat diet-induced NASH has previously reported both anti-inflammatory and anti-fibrotic effects (22), detailed mechanistic understanding is still lacking.

In the present study, we aimed to elucidate the mechanisms underlying FGF21-mediated improvement of NASH, in particular of steatohepatitis and fibrogenesis. To this end, we used APOE*3-Leiden.CETP mice, a well-established model for human cardiometabolic diseases. These mice exhibit human-like lipoprotein metabolism, develop hyperlipidemia, obesity and inflammation when fed a high-fat high-cholesterol diet (HFCD), and develop fibrotic NASH closely resembling clinical features that accompany NASH in humans (23, 24). Moreover, these mice show human-like responses to both lipid-lowering and anti-inflammatory therapeutics during the development of metabolic syndrome (25-28). Here, we show that specific overexpression of FGF21 in the liver, resulting in increases circulating FGF21 levels, activates hepatic signaling associated with FA oxidation and cholesterol removal. In parallel, FGF21 activates thermogenic tissues and reduces adipose tissue inflammation, thereby protecting against adipose tissue dysfunction, hyperglycemia and hypertriglyceridemia. As a consequence, FGF21 largely limits lipid accumulation in the liver and potently blocks hepatic KC activation and monocyte recruitment, thereby preventing the accumulation of pro-inflammatory macrophages in the liver. In addition, FGF21 reduced the number of pro-fibrotic macrophages in the injured liver, potentially explaining why FGF21 counteracts all features of NASH, including hepatic steatosis, inflammation and fibrogenesis.

Results

Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain

We aimed to elucidate the underlying mechanisms of FGF21-mediated hepatoprotective effects on NASH, by using APOE*3-Leiden.CETP mice fed with a HFCD, a model that induces all stages of NASH in a human-like fashion and recapitulates the ultrastructural changes observed in NASH patients (23, 24). Since the liver is the main contributor to circulating FGF21 (14), we employed an adeno-associated virus vector 8 (AAV8) vector expressing codon-optimized FGF21 to induce liver-specific FGF21 overexpression in APOE*3-Leiden.CETP mice. Mice treated with either AAV8-FGF21 or AAV8-null as controls were fed with a HFCD for 23 weeks (**Figure 1A**). We confirmed liver-specific FGF21 overexpression by a large increase in *Fgf21* expression in the liver but not in adipose tissue, resulting in high circulating FGF21 levels that persisted throughout the study (**Figure 1B**). HFCD progressively and profoundly increased body weight over the experimental period, accompanied by increased white adipose tissue (WAT) and brown adipose tissue (BAT) weights relative to those of low fat low cholesterol (LFCD)-fed mice (**Figure 1C,D**). In favorable contrast, FGF21 reduced body weight in the first 3 weeks, after which body weight stabilized and remained lower than that of LFCD- and HFCD-fed mice by the end of the study (-18% and -35%, respectively; **Figure 1C**). Concomitantly, FGF21 decreased weights of gonadal WAT (gWAT; -67%), subcutaneous WAT (sWAT; -55%), interscapular BAT (iBAT; -41%) and subscapular BAT (-41%) to levels comparable to those observed in LFCD-fed mice (**Figure 1D**). These findings thus highlight the potent effects of FGF21 on preventing fat mass gain under NASH-inducing dietary conditions.

FGF21 protects against HFCD-induced adipose tissue dysfunction

The profound fat mass-lowering effects of liver-derived FGF21 prompted us to examine its role in adipose tissue function. Since we and others have previously shown that FGF21 activates thermogenic adipose tissues (29, 30), we first performed histological analyses of BAT and sWAT, the adipose tissue that is most prone to browning (31). We observed that FGF21 prevented the HFCD-induced lipid overload in BAT (-66%) and increased uncoupling protein-1 (UCP-1) expression compared with both the LFCD- and HFCD-fed groups (+15% and +26%, respectively) (**Figure 2A**). In sWAT, FGF21 prevented HFCD-induced adipocyte hypertrophy (-41%), and increased the UCP-1 content (+94%) (**Figure 2B**). Among the adipose tissue depots, gWAT is most prone to diet-induced inflammation, and surgical removal of inflamed gWAT attenuates NASH in obese mice (32). Similar to sWAT, FGF21 protected against HFCD-induced adipocyte enlargement (-52%) in gWAT and in addition fully prevented the formation of crown-like structures (CLSs; -93%) (**Figure 2C**). In agreement with these findings, FGF21 suppressed the HFCD-induced expression of adhesion G protein-coupled receptor E1 (*Adgre1*; -56%), encoding the macrophage surface marker F4/80, in addition to decreased expression of the pro-inflammatory mediators tumor necrosis factor α (*Tnfa*; -60%), interleukin-1 β (*Il1b*; -50%) and monocyte attractant chemokine C-C motif ligand 2 (*Ccl2*; -60%) (**Figure 2D**). Besides, FGF21 tended to upregulate *Klb* (+33%) and *Fgfr1* (+30%) expression compared to HFCD-fed mice (**Figure 2-figure supplement 1**). Moreover, consistent with the critical role of adiponectin in mediating the therapeutic benefits of FGF21 in adipose tissue(22, 33), FGF21 increased plasma adiponectin levels compared to both LFCD- and HFCD-fed mice (+93% and +133%, respectively; **Figure 2E**). These combined findings thus indicate that FGF21 prevents HFCD-induced adipose tissue dysfunction during NASH development.

FGF21 alleviates HFCD-induced hyperglycemia and hypertriglyceridemia

We next examined whether FGF21 confers its glucose and lipid lowering effects during NASH development. While HFCD induced hyperglycemia as compared to LFCD, FGF21 normalized fasting plasma glucose compared to LFCD, which was accompanied by lower glucose excursion after an intraperitoneal glucose tolerance test (**Figure 3A,B**). In addition, FGF21 normalized the plasma insulin and Homeostatic Model Assessment for Insulin Resistance index (**Figure 3C**), indicating that FGF21 restores insulin sensitivity to that observed in LFCD-fed mice. FGF21 did not prevent the HFCD-induced increase of plasma total cholesterol (TC) levels (**Figure 3-figure supplement 1A**), nor the distribution of cholesterol over the various lipoproteins (**Figure 3-figure supplement 1B**). Nonetheless, FGF21 strongly and consistently reduced fasting plasma triglyceride (TG) levels throughout the experimental period compared with LFCD- and HFCD-fed mice (-67% and -58%; at week 22), which was specific for very-low density lipoprotein (VLDL) and low density lipoprotein (LDL) (**Figure 3D**). In addition, an oral lipid tolerance test revealed that FGF21 prevented HFCD-induced lipid intolerance (**Figure 3E**). Taken together, FGF21 prevents the HFCD-induced increase in circulating glucose and reduces circulating TG levels beyond those observed in LFCD-fed mice.

FGF21 protects against HFCD-induced hepatic steatosis, inflammation, and fibrogenesis

Then, we investigated the effects of FGF21 on liver steatosis, inflammation and fibrosis. FGF21 not only prevented HFCD-induced liver weight gain (-58%), but even reduced liver weight to a level lower than that of LFCD-fed mice (-40%; **Figure 4A,F**). Moreover, FGF21 abolished the HFCD-induced increase in steatosis, lobular inflammation and hepatocellular ballooning (**Figure 4B, Figure 4-figure supplement 1A,B**). Therefore, FGF21 completely prevented the HFCD-induced large increase in the NAFLD activity score (-74%; **Figure 4C,F**). Furthermore, FGF21 prevented collagen accumulation in the liver as assessed by

Picrosirius Red staining (-58%; **Figure 4D,F**). We then measured hepatic concentration of hydroxyproline, a major constituent of collagen and thus a marker of extracellular matrix accumulation. In line with the hepatic collagen content, HFCD feeding increased the hepatic hydroxyproline content, which was prevented by FGF21 (-49%; **Figure 4E**). Taken together, our data demonstrate that FGF21 protects against HFCD-induced hepatosteatosis, steatohepatitis as well as fibrogenesis.

FGF21 abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in FA oxidation and cholesterol removal

In the context of NASH, pro-inflammatory responses and fibrogenesis occur when hepatocytes are injured by lipotoxicity (7, 34). Indeed, 23 weeks of HFCD feeding promoted aberrant accumulation of TG as well as TC in the liver (**Figure 5A**). In agreement with the data presented in **Figure 4**, FGF21 abrogated the HFCD-induced increase in hepatic TG levels (-62%) and tended to decrease hepatic TC levels (-22%), resulting in smaller lipid droplets (**Figure 5A**). In addition to reduced lipid overflow from WAT, we reasoned that FGF21 may also directly act on the liver to prevent HFCD-induced liver lipotoxicity. In agreement, compared to both LFCD- and HFCD-fed mice, FGF21 profoundly upregulated the expression of *Klb* (+150% and +223%), *Fgfr1* (+57% and +79%), *Fgfr2* (+97% and +77%), and *Fgfr4* (+53% and +67%) (**Figure 5-figure supplement 1**). We next quantified the hepatic expression of key genes involved in FA and cholesterol handling. FGF21 did not attenuate the HFCD-induced increased expression of FA translocase cluster of differentiation 36 (*Cd36*) (**Figure 5-supplement 2A**). In favorable contrast, compared to both LFCD- and HFCD-fed mice, FGF21 did increase the expression of carnitine palmitoyl transferase 1 α (*Cpt1a*, +66% and +53%), peroxisome proliferator-activated receptor α (*Ppara*, +67% and +53%) and peroxisome proliferator-activated receptor γ coactivator 1 α (*Pgc1a*; +188% and +225%), all of those genes being key players involved in FA oxidation

(**Figure 5B**). Moreover, compared to LFCD- and HFCD-fed mice, FGF21 increased the expression of apolipoprotein B (*Apob*, +26% and +38%), which is involved in VLDL secretion (**Figure 5-figure supplement 2B**). Furthermore, FGF21 upregulated the expression of ATP-binding cassette transporter G member 5 (*Abcg5*; 7-fold and 2-fold), crucial for biliary secretion of neutral sterols (**Figure 5C**), increased the expression of cholesterol 7 α -hydroxylase (*Cyp7a1*; +94% and +109%), a key gene involved in the classic bile acid synthesis pathway (**Figure 5D**), and restored the expression of sterol 27-hydroxylase (+38%), involved in the alternative bile acid pathway (**Figure 5D**). Considering that bile acid synthesis is a major pathway for hepatic cholesterol disposal (35), FGF21 likely regulates bile acid metabolism to prevent HFCD-induced cholesterol accumulation in the liver. Collectively, our data indicate that FGF21 increases the hepatic expression of key genes involved in β -oxidation and cholesterol removal, which together with reduced lipid overload from WAT may explain FGF21-induced alleviation of liver lipotoxicity under NASH-inducing dietary conditions.

FGF21 prevents activation of various KC subsets

Then, we performed an in-depth phenotyping of hepatic immune cells using spectral flow cytometry. For this, we developed a panel that identifies most major immune cell subsets (for gating strategy see **Figure 6-figure supplement 1A**). As compared to LFCD, HFCD tended to reduce total CD45⁺ leukocytes, which were increased by FGF21 (**Figure 6-figure supplement 1B**). Combining conventional gating and dimension-reduction analysis through uniform manifold approximation and projection allowed to identify FGF21-induced changes in cell subset abundance (**Figure 6A**). FGF21 prevented HFCD-induced loss of eosinophils, neutrophils and B cells, and increased numbers of dendritic cells and T cells compared with those observed in both LFCD- and HFCD-fed mice (**Figure 6-figure supplement 1B**). More importantly, FGF21 increased the number of total KCs compared with that of both

LFCD- and HFCD-fed mice (+63% and +156; **Figure 6-figure supplement 1B**), attenuated HFCD-induced monocyte recruitment (-18%), and tended to repress the HFCD-induced increase in hepatic MoDMacs (-42%; **Figure 6-figure supplement 1B**).

During the development of NASH, MoDMacs can gradually seed in KC pool by acquiring ResKCs identity and replacing the dying ResKCs (36). These recruited MoKCs can have both detrimental and supportive roles, contributing to increase in pathology during fibrosis onset, but hastening recovery when the damage-evoking agent is attenuated/removed (37). In light of this, we assessed the abundance and phenotype of ResKCs and monocyte-derived KCs (MoKCs). We observed that FGF21 completely abolished the HFCD-induced reduction of the number of ResKCs (+319%) and potentially protected against HFCD-induced ResKC activation as shown by decreased proportion of CD11c⁺ ResKCs (-53%; **Figure 6B**). FGF21 also completely abolished the HFCD-induced upregulation of CD36 in ResKCs, to levels that are even lower than those in LFCD-fed mice (-88% vs. LFCD; -94% vs. HFCD; **Figure 6B**). In addition, FGF21 increased the number of MoKCs compared with that of both LFCD- and HFCD-fed mice (+92% and +123%), and prevented the HFCD-induced increase in the abundance of CD11c⁺ MoKCs (-42%) (**Figure 6C**). Strikingly, compared to both LFCD- and HFCD-fed mice, FGF21 downregulated CD9 (-32% and -49%) and CD36 (-98% and -100%) in MoKCs (**Figure 6C**). Furthermore, FGF21 profoundly repressed HFCD-induced upregulation of hepatic *Tnfa* (-37%), *Il1b* (-41%) and *Ccl2* (-54%) expression to levels comparable to those in LFCD-fed mice (**Figure 6D**), which is in line with the observation that FGF21 prevents KC activation. Given that CD36^{hi} ResKCs and CD36^{hi}/CD9^{hi} MoKCs are involved in the formation of hepatic CLSs(10, 37-39), we next assessed CLSs and observed that FGF21 completely prevented the HFCD-induced formation of CLSs in the liver (-93%; **Figure 6D**). These data demonstrate that FGF21 inhibits the activation of ResKCs and MoKCs and prevents the accumulation of CD36^{hi} ResKCs and

CD36^{hi}/CD9^{hi} MoKCs under dietary conditions that result in NASH, which likely contribute to the beneficial effects of FGF21 on hepatic inflammation and fibrosis.

FGF21 protects against COL1A1 accumulation, as predicted by the reduction of CD36^{hi} KCs and CD9^{hi} KCs

To further evaluate whether FGF21-induced reductions of lipid-associated macrophages (i.e., CD36^{hi} ResKCs and CD36^{hi} MoKCs) (38) and scar-associated macrophages (i.e., CD9^{hi} MoKCs) (40), are implicated in fibrogenesis, we performed multiple univariate regression analyses. These revealed that both NAFLD activity and liver fibrosis were associated with both CD36^{hi} ResKCs, CD36^{hi} MoKCs and CD9^{hi} MoKCs (**Figure 6-figure supplement 2A-D**), indicating that FGF21 likely improves liver fibrosis by reducing these lipid- and scar-associated macrophages. To further understand the underlying mechanisms by which FGF21 prevents liver fibrosis, we measured hepatic expression of key genes involved in fibrogenesis (**Figure 6D**). FGF21 tended to decrease the expression of connective tissue growth factor (*Ctgf*, -27%), a major fibrogenic factor, and normalized the HFCD-induced increased expression of its downstream target collagen type Iα 1 (*Col1a1*; -61%; **Figure 6D**). This finding was confirmed by immunohistochemistry, revealing that FGF21 reduced hepatic COL1A1 accumulation (-46%; **Figure 6D**). Furthermore, univariate regression analysis revealed that COL1A1 expression is predicted by CD36^{hi} ResKCs, CD36^{hi} MoKCs and CD9^{hi} MoKCs (**Figure 6E, Figure 6-figure supplement 2E**). Taken together, these data indicate that FGF21 reduces lipid- and scar-associated macrophages to inhibit COL1A1 synthesis and prevent fibrogenesis.

Discussion

Several FGF21 analogues are currently being evaluated in clinical trials for the treatment of NASH (20, 21). While the protective effect of pharmacological intervention with long-acting FGF21 on human liver steatosis has been uncovered (20, 21, 41), mechanisms underlying attenuated steatosis as well all the anti-inflammatory and anti-fibrotic effects of FGF21 on NASH are still largely unexplored. Therefore, we set out to elucidate mechanisms by which FGF21 beneficially modulates these various aspects of NASH in HFCD-fed APOE*3-Leiden.CETP mice, a well-established model for diet-induced NASH (23, 24). Based on our findings, we propose that FGF21 attenuates liver lipotoxicity via endocrine signaling to adipose tissue to induce thermogenesis, thereby preventing adipose tissue dysfunction to reduce lipid overflow to the liver, as well as autocrine signaling to the liver to increase FA oxidation and cholesterol removal. In addition, FGF21 prevents KC activation, monocyte recruitment and the formation of lipid- and scar-associated macrophages, thereby likely inhibiting collagen accumulation and alleviating liver fibrogenesis.

Hepatic lipotoxicity is one of the major risk factors determining the progression of liver steatosis into NASH, as shown in multiple clinical studies with obese patients (42-44). By feeding APOE*3-Leiden.CETP mice a diet rich in fat and cholesterol, we mimicked a situation in which a positive energy balance induces many aspects of the metabolic syndrome, including insulin resistance, obesity with increased fat accumulation, and hepatic lipotoxicity indicated by hepatomegaly with aberrant accumulation of TG as well as TC. Hepatic lipotoxicity likely results from lipid overflow from insulin-resistant adipose tissue towards the liver in combination with hepatic insulin resistance that prevents insulin-stimulated outflow of lipids (45). Within this dietary context, we applied a single administration of an AAV8 vector encoding codon-optimized FGF21, which resulted in liver-specific FGF21 overexpression. Since the codon-optimized FGF21 mitigates the poor

pharmacokinetic properties of native FGF21, including its short plasma half-life (0.5-2 hours) by reducing proteolytic degradation(45), an elevated level of circulating FGF21 was reached throughout the dietary intervention period. By this strategy, we mimicked the situation in which circulating FGF21 predominantly derives from the liver (46). Indeed, circulating FGF21 correlates well with the hepatic expression of FGF21 (47). Interestingly, hepatic expression of FGF21 fully prevented the diet-induced increase in liver weight, liver lipids (i.e., TG and TC) and steatosis score.

These lipotoxicity-protective effects of FGF21 can partially be explained by endocrine effects of liver-derived FGF21 on adipose tissue, which besides the liver has high expression of β -Klotho, the co-receptor of the FGFR (14, 15). Indeed, FGF21 fully prevented the HFCD-induced increase in weights of WAT and BAT, with decreased lipid accumulation in these adipose tissue depots as well as induction of BAT activation and WAT browning. These data imply that FGF21 greatly induces thermogenesis which highly increases energy expenditure, consistent with the thermogenic responses observed for recombinant FGF21 in mice fed with an obesogenic diet (29) or atherogenic diet (30). Activation of thermogenic tissues by classical β -adrenergic receptor largely increases the uptake of circulating lipoprotein-derived FAs by BAT and beige WAT (48), which we recently also demonstrated for recombinant FGF21 (30). This can thus at least partly explain the marked TG-lowering effect of FGF21 observed in the current study. Thermogenic activation also increases the uptake and combustion of glucose, although the glucose-lowering and insulin-sensitizing effects of FGF21 can also be explained by attenuated WAT inflammation in combination with increased adiponectin expression as well as improved liver insulin sensitivity (30, 33, 49).

Besides endocrine FGF21 signaling in adipose tissue, liver lipotoxicity is likely further prevented by autocrine FGF21 signaling. Indeed, we showed that liver-specific FGF21 overexpression increased hepatic expression of genes involved in FA oxidation (*Cpt1a*, *Ppara*, *Pgc1a*), biliary cholesterol secretion (*Abcg5*), bile acids synthesis (*Cyp7a1*) and VLDL production (*Apob*). Of note, these observations are in line with previous reports showing increased FA oxidation (50) and upregulated *Abcg5* (51), *Cyp7a1* (51, 52) and *Apob* (30) in the liver upon FGF21 treatment. Altogether, the marked protective effects of FGF21 on HFCD-induced hepatic lipotoxicity likely results from combined endocrine and autocrine signaling, leading to reduced lipid influx from adipose tissue to the liver coupled to the activation of hepatic FA oxidation and cholesterol elimination pathways. Our observations may likely explain the recent clinical findings that treatment with FGF21 analogues in patients with NASH not only reduced hepatic steatosis (20, 21) but also increased hepatic bile acid synthesis and further promoted cholesterol removal, lowering the risk for further hepatic lipotoxicity (53).

While NASH is initiated by hepatic lipotoxicity, NASH progression is mainly driven by impaired KC homeostasis and subsequent liver inflammation (54). Therefore, we investigated in depth the inflammatory response in the liver through a combination of immunohistochemistry, flow cytometry and gene expression analyses. HFCD feeding induced an array of inflammatory effects, including increased lobular inflammation, hepatocyte ballooning and NAFLD activity scores as well as increased inflammatory foci and CLSs, accompanied by a reduction in ResKCs with a relative increase in CD11c⁺ ResKCs, and an increase in MoDMacs and CD11c⁺ MoKCs. These observations are likely explained by lipotoxicity-related damage to ResKCs, and release of TNF α , IL-1 β and MCP-1 (*Ccl2*), both activating various downstream pro-inflammatory mediators as well as promoting monocyte recruitment to remodel the KC pool(36, 55) and further exacerbating

hepatic inflammation (10, 38, 54, 56, 57). Importantly, FGF21 prevented most of these HFCD-induced inflammatory responses, as it normalized lobular inflammation, hepatocyte ballooning and NAFLD activity scores and CLSs, and reduced pro-inflammatory activation of various KC subsets.

Fibrosis has been identified as the most important predictor of prognosis in NAFLD patients, and therefore a main target in experimental pharmacological approaches (58). HFCD feeding during 23 weeks induced early signs of fibrosis, as evident from an increased *Col1a1* expression and COL1A1 content, accompanied by an increased content of the hydroxyproline. Importantly, FGF21 blocked liver fibrogenesis, and decreased the hydroxyproline content. These alterations were accompanied with reductions in lipid-associated macrophages (i.e., CD36^{hi} ResKCs/MoKCs) (38) and scar-associated macrophages (i.e., CD9^{hi} MoKCs) (40). In fact, when analysing the mouse groups together, CD36^{hi} ResKCs/MoKCs and CD9^{hi} MoKCs positively correlated with liver fibrosis as reflected by hydroxyproline content and COL1A-positive area, suggesting that these lipid- and scar-associated macrophages are involved in fibrogenesis in our model. Indeed, high numbers of CD9^{hi} macrophages have been found in fibrotic regions of the liver (37, 39, 40, 55), and these cells are able to prime quiescent primary murine hepatic stellate cells to upregulate the expression of fibrillar collagen through CTGF (40), thereby promoting and exacerbating liver fibrosis. Therefore, we speculate that FGF21 protects against early liver fibrosis likely through preventing the accumulation of CD36^{hi}/CD9^{hi} KCs, thereby inhibiting activation of hepatic stellate cells to produce collagen.

In conclusion, hepatic overexpression of FGF21 in APOE*3-Leiden.CETP mice limits diet-induced hepatic lipotoxicity, inflammation and fibrogenesis. Through a combination of endocrine and autocrine signaling, FGF21 reduces hepatic lipid influx and accumulation,

417 respectively. This results in reduced macrophage activation and monocyte recruitment with
 418 less presence of lipid- and scar-associated macrophages, limiting activation of hepatic
 419 stellate cells to produce collagen (for graphic summary see **Figure 6F**). As such, our
 420 studies provide a mechanistic explanation for the hepatoprotective effects of FGF21
 421 analogues in recent clinical trials including reduction in steatosis (20, 21, 53) as well as the
 422 fibrotic marker N-terminal type III collagen pro-peptide (20, 21), and further highlight the
 423 potential of FGF21 for clinical implementation as a therapeutic in the treatment of advanced
 424 NASH.

Materials and Methods

Please see the **Supporting Information** for a detailed description of all experimental procedures.

Animals and treatments

Male APOE*3-Leiden.CETP mice (on a C57BL/6J background) were generated as previously described (59). Mice at the age of 10-12 weeks were group-housed (2-4 mice per cage) under standard conditions (22°C, 12/12-hour light/dark cycle) with *ad libitum* access to water and a LFCD (Standard Rodent Diet 801203, Special Diets Services, United Kingdom), unless indicated otherwise. Then, based on body weight and 4-hour (9.00-13.00) fasted plasma glucose, TG and TC levels, these mice were randomized into three treatment groups (n = 18 per group), after which they received either AAV8-FGF21, a liver-tropic AAV8 capsid vector expressing FGF21 under the control of a liver specific apolipoprotein E /antitrypsin promoter (HFCD+FGF21 group; 2×10^{10} genome copies per mouse), or with the same genome copy number of AAV8-null (HFCD and LFCD groups) via a single intravenous injection. After one week of recovery, mice in the HFCD+FGF21 and HFCD groups were switched to a HFCD (60% fat and 1% cholesterol; C1090-60, Altromin, Germany) and maintained on the diet for 23 weeks. An intraperitoneal glucose tolerance test (n = 8 per group) and an oral lipid tolerance test (n = 10 per group) were performed at week 16 and week 20, respectively. Flow cytometry (n = 5 per group) was conducted at week 23.

Statistics

Comparisons among three groups were analyzed using one-way ANOVA followed by a Tukey post-test, unless indicated otherwise. Data are presented as mean \pm SEM, and a *P* value of less than 0.05 was considered statistically significant. All statistical analyses were

451 performed with GraphPad Prism 9.01 for Windows (GraphPad Software Inc., California, CA,
452 USA).

453

454 **Study approval**

455 All animal experiments were carried out according to the Institute for Laboratory Animal
456 Research Guide for the Care and Use of Laboratory Animals, and were approved by the
457 National Committee for Animal Experiments (Protocol No. AVD1160020173305) and by the
458 Ethics Committee on Animal Care and Experimentation of the Leiden University Medical
459 Center (Protocol No. PE.18.034.041).

Acknowledgments

This work was supported by the Dutch Diabetes Research Foundation (2015.81.1808 to M.R.B.); the Netherlands Organisation for Scientific Research-NWO (VENI grant 91617027 to Y.W.); Chinese Scholarship Council grants (CSC 201606010321 to E.Z.); the Novo Nordisk Foundation (NNF18OC0032394 to M.S.); and the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON-GENIUS-2 to P.C.N.R.). The authors also thank T.C.M. Streefland, A.C.M. Pronk, R.A. Lalai and H.C.M. Sips from Department of Medicine, the Division of Endocrinology, Leiden University Medical Center for technical assistance.

Conflict of interest:

ACA, AP, SO, MU, IA, YI, KW and XRP are employees of AstraZeneca.

Data availability:

All data generated or analyzed during this study are included in the manuscript and supporting file.

Author contributions:

CL designed the study, carried out the research, analyzed and interpreted the results, and wrote and revised the manuscript. MS interpreted the results, reviewed and revised the manuscript and obtained the funding. BS and EZ carried out the research and reviewed the manuscript. JML, HJPZ and BG designed and advised the study, interpreted the results and reviewed the manuscript. MET advised the study and reviewed the manuscript. ACA, SO and KW advised the study, interpreted the results and reviewed the manuscript. AP designed AAV8-FGF21 vectors and edited the manuscript. MU and IA analyzed and

486 interpreted the results and reviewed the manuscript. YI and X-RP provided AAV8-FGF21
487 vectors, advised the study, interpreted the results and reviewed the manuscript. MRB
488 advised the study and reviewed the manuscript. YW designed and advised the study,
489 interpreted the results, reviewed and revised the manuscript. PCNR designed and advised
490 the study, interpreted the results, edited, reviewed and revised the manuscript and obtained
491 the funding.

References

1. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. *Gastroenterology*. 2012;142(4):711-725.e6.
2. Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med*. 2018;24(7):908-922.
3. Arab JP, et al. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. *Annu Rev Pathol-Mech*. 2018;13:321-350.
4. Taylor RS, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta -Analysis. *Gastroenterology*. 2020;158(6):1611-1625.e12.
5. Stefan N, et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. *Lancet Diabetes Endocrinol*. 2019;7(4):313-324.
6. Musso G, et al. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). *Prog Lipid Res*. 2009;48(1):1-26.
7. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. *Hepatology*. 2010;52(2):774-788.
8. Tacke F. Targeting hepatic macrophages to treat liver diseases. *J Hepatol*. 2017;66(6):1300-1312.
9. Krenkel O, and Tacke F. Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol*. 2017;17(5): 306-321.
10. Tran S, et al. Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis. *Immunity*. 2020;53(3):627-640.e5.
11. Krenkel O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. *Hepatology*. 2018;67(4):1270-1283.

- 517 12. Meng W, et al. The miR-182-5p/FGF21/acetylcholine axis mediates the crosstalk between
518 adipocytes and macrophages to promote beige fat thermogenesis. *JCI Insight*.
519 2021;6(17):e150249.
- 520 13. Guo Y, et al. Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to
521 affect macrophage actions. *Lipids Health Dis*. 2016;15(1):208.
- 522 14. Fisher FM, and Maratos-Flier E. Understanding the Physiology of FGF21. *Annu Rev*
523 *Physiol*. 2016;78:223-241.
- 524 15. Geng L, et al. The therapeutic potential of FGF21 in metabolic diseases: from bench to
525 clinic. *Nat Rev Endocrinol*. 2020;16(11):654-667.
- 526 16. Zhang X, et al. Serum FGF21 levels are increased in obesity and are independently
527 associated with the metabolic syndrome in humans. *Diabetes*. 2008;57(5):1246-1253.
- 528 17. Barb D, et al. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of
529 Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. *J Clin*
530 *Endocrinol Metab*. 2019;104(8):3327-3336.
- 531 18. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, et al. Fibroblast growth factor 21 levels are
532 increased in nonalcoholic fatty liver disease patients and are correlated with hepatic
533 triglyceride. *J Hepatol*. 2010;53(5):934-940.
- 534 19. Flippo KH, and Potthoff MJ. Metabolic Messengers: FGF21. *Nat Metab*. 2021;3(3):309-317.
- 535 20. Sanyal A, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21
536 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind,
537 placebo-controlled, phase 2a trial. *Lancet*. 2019;392(10165): 2705-2717.
- 538 21. Harrison SA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-
539 blind, placebo-controlled, phase 2a trial. *Nat Med*. 2021;27(7):1262-1271.
- 540 22. Bao LC, et al. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a
541 mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A
542 pathway. *Brit J Pharmacol*. 2018;175(16):3379-3393.

- 543 23. Morrison MC, et al. Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-
544 alcoholic steatohepatitis and associated fibrosis in ApoE(*) 3Leiden mice. *J Hepatol.*
545 2015;62(5):1180-1186.
- 546 24. Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of
547 a general NAFLD scoring system for rodent models and comparison to human liver
548 pathology. *PLoS One.* 2014;9(12):e115922.
- 549 25. van den Hoek AM, et al. APOE*3Leiden.CETP transgenic mice as model for
550 pharmaceutical treatment of the metabolic syndrome. *Diabetes Obes Metab.*
551 2014;16(6):537-544.
- 552 26. van der Hoorn JW, et al. The dual PPARalpha/gamma agonist tesaglitazar blocks
553 progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. *Br J*
554 *Pharmacol.* 2009;156(7):1067-1075.
- 555 27. Li Z, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain
556 neural circuit. *Gut.* 2018;67(7):1269-1279.
- 557 28. Duivenvoorden I, et al. Dietary sphingolipids lower plasma cholesterol and triacylglycerol
558 and prevent liver steatosis in APOE*3Leiden mice. *Am J Clin Nutr.* 2006;84(2):312-321.
- 559 29. Schlein C, et al. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein
560 Catabolism in White and Brown Adipose Tissues. *Cell Metab.* 2016;23(3):441-453.
- 561 30. Liu C, et al. Pharmacological treatment with FGF21 strongly improves plasma cholesterol
562 metabolism to reduce atherosclerosis. *Cardiovasc Res.* 2022;118(2):489-502.
- 563 31. Zhang F, et al. An Adipose Tissue Atlas: An Image-Guided Identification of Human-like
564 BAT and Beige Depots in Rodents. *Cell Metab.* 2018;27(1):252-262.e3.
- 565 32. Mulder P, et al. Surgical removal of inflamed epididymal white adipose tissue attenuates
566 the development of non-alcoholic steatohepatitis in obesity. *Int J Obes (Lond).*
567 2016;40(4):675-684.

- 568 33. Lin Z, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis
569 and insulin sensitivity in mice. *Cell Metab.* 2013;17(5):779-789.
- 570 34. Machado MV, and Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis.
571 *Gastroenterology.* 2016;150(8):1769-1777.
- 572 35. Tu H. FXR, a Bile Acid Receptor and Biological Sensor. *Trends in Cardiovascular*
573 *Medicine.* 2000;10(1):30-35.
- 574 36. Tran S, et al. Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid
575 Overload during Non-alcoholic Steatohepatitis. *Immunity.* 2020;53(3):627-640.e5.
- 576 37. Seidman JS, et al. Niche-Specific Reprogramming of Epigenetic Landscapes Drives
577 Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. *Immunity.* 2020;52(6):1057-1074.e7.
- 578 38. Blieriot C, et al. A subset of Kupffer cells regulates metabolism through the expression of
579 CD36. *Immunity.* 2021;54(9):2101-2116.e6.
- 580 39. Daemen S, et al. Dynamic Shifts in the Composition of Resident and Recruited
581 Macrophages Influence Tissue Remodeling in NASH. *Cell Rep.* 2021;34(2):108626.
- 582 40. Ramachandran P, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell
583 level. *Nature.* 2019;575(7783):512-518.
- 584 41. Aggarwal P, et al. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic
585 agents in clinical development and the optimal design for clinical trials. *Expert Opin Inv*
586 *Drug.* 2022, 31(2):163-172.
- 587 42. Bril F, et al. Metabolic and histological implications of intrahepatic triglyceride content in
588 nonalcoholic fatty liver disease. *Hepatology.* 2017;65(4):1132-1144.
- 589 43. Armstrong MJ, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic
590 steatohepatitis. *J Hepatol.* 2016;64(2):399-408.
- 591 44. Ratzliff V, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized,
592 double-blind, placebo-controlled phase 2b trial. *Nat Med.* 2021;27(10):1825-1835.

- 593 45. Zarei M, et al. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. *Trends*
594 *Pharmacol Sci.* 2020;41(3):199-208.
- 595 46. Nishimura T, Nakatake Y, Konishi M, and Itoh N. Identification of a novel FGF, FGF-21,
596 preferentially expressed in the liver. *Biochim Biophys Acta.* 2000;1492(1):203-206.
- 597 47. Markan KR, et al. Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake
598 During Refeeding and Overfeeding. *Diabetes.* 2014;63(12):4057-4063.
- 599 48. Berbee JF, et al. Brown fat activation reduces hypercholesterolaemia and protects from
600 atherosclerosis development. *Nat Commun.* 2015;6:6356.
- 601 49. Yang Q, et al. Metabolites as regulators of insulin sensitivity and metabolism. *Nat Rev Mol*
602 *Cell Biol.* 2018;19(10):654-672.
- 603 50. Fisher FM, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty
604 acid activation in mice on methionine and choline-deficient diets. *Gastroenterology.*
605 2014;147(5):1073-83.e6.
- 606 51. Keinicke H, et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and
607 inflammation. *Endocr Connect.* 2020;9(8):755-768.
- 608 52. Zhang J, et al. Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile
609 Acid Biosynthesis by Opposing FGF15/19 Action. *EBioMedicine.* 2017;15:173-183.
- 610 53. Luo Y, et al. Pegbelfermin selectively reduces secondary bile acid concentrations in
611 patients with non-alcoholic steatohepatitis. *JHEP Rep.* 2021;4(1):100392.
- 612 54. Cai J, et al. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. *Hepatology.*
613 2019;70(3):1026-1037.
- 614 55. Remmerie A, et al. Osteopontin Expression Identifies a Subset of Recruited Macrophages
615 Distinct from Kupffer Cells in the Fatty Liver. *Immunity.* 2020;53(3):641-657.e14.
- 616 56. Schwabe RF, et al. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.
617 *Gastroenterology.* 2020;158(7):1913-1928.

- 618 57. Yu Y, et al. STING-mediated inflammation in Kupffer cells contributes to progression of
619 nonalcoholic steatohepatitis. *J Clin Invest.* 2019;129(2):546-555.
- 620 58. Heyens LJM, et al. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy
621 to Non-invasive Biomarkers in Diagnosis and Treatment. *Front Med (Lausanne).*
622 2021;8:615978.
- 623 59. Westerterp M, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein
624 and severely aggravates atherosclerosis in APOE*3-Leiden mice. *Arterioscler Thromb Vasc*
625 *Biol.* 2006;26(11):2552-2559.

626

Figure legends:

Figure 1. Liver-specific FGF21 overexpression increases circulating FGF21 levels

and protects against HFCD-induced body fat mass gain. (A) Experimental set up. (B) At week 23, FGF21 mRNA expression in the liver and gWAT was quantified (n = 16-18). Plasma FGF21 levels were measured before (at week -1; pooled samples, n = 6 per group) and after (at week 4, pooled samples, n = 6 per group; week 23, n = 12-16 per group) AAV8-FGF21 administration. (C) Body weight was monitored throughout the experimental period (n = 17-18). (D) At week 23, brown adipose tissue (BAT) and white adipose tissue (WAT) depots were isolated and weighed (n = 18). Data are shown as mean \pm SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. * P < 0.05; ** P < 0.01, *** P < 0.001, compared with the LFCD group. #### P < 0.001, compared with the HFCD group. AAV8, adeno-associated virus 8; FGF21, fibroblast growth factor 21; gWAT, gonadal WAT; HFCD, high fat and high cholesterol diet; iBAT, interscapular BAT; LFCD, low fat and low cholesterol diet; sBAT, subscapular BAT; sWAT, subcutaneous white adipose tissue.

Figure 2. FGF21 protects against HFCD-induced adipose tissue dysfunction. (A) In

iBAT, the lipid content and expression of uncoupling protein-1 (UCP-1) were quantified after H&E staining and UCP-1 immunostaining, respectively. (B) In sWAT, the adipocyte enlargement was assessed by H&E staining, and the tissue browning was evaluated by UCP-1 immunostaining. (C) In gWAT, the adipocyte hypertrophy was detected, and the number of CLSs was assessed, and (D) mRNA expression of pro-inflammatory markers was quantified. (E) Plasma adiponectin concentration in fasted blood plasma was measured at week 22. (A)-(D), n = 14-18 per group; (E), n = 10 per group. Differences were assessed using one-way ANOVA followed by a Tukey post-test. * P < 0.05, *** P < 0.001,

compared with the LFCD group. $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, $^{\#\#\#}P < 0.001$, compared with the HFCD group. *Adgre1*, adhesion G protein-coupled receptor E1; *Tnfa*, tumor necrosis factor α ; *Il1b*, interleukin-1 β ; *Ccl2*, chemokine C–C motif ligand 2.

Figure 3. FGF21 alleviates HFCD-induced hyperglycemia and hypertriglyceridemia. (A)

Fasting plasma glucose levels were measured during the experimental period. (B) At week 16, an intraperitoneal glucose tolerance test (IPGTT) was initiated. (B) The area under the curve (AUC) of plasma glucose during the IPGTT and (C) plasma insulin concentration in response to the IPGTT was determined at the indicated timepoints. (C) Homeostasis model assessment of insulin resistance (HOMA-IR) was determined from fasting glucose and insulin levels. (D) Fasting plasma TG levels were measured throughout the study. The distribution of triglyceride over lipoproteins was determined (pooled samples; n = 5 per group) from plasma of week 22. (E) At week 20, an oral lipid tolerance test (OLTT) was initiated, and AUC of plasma TG during the OLTT was calculated. (A and D), n = 14-18 per group; (B-C), n = 7-8 per group; (E), n = 6-9 per group. Data are shown as mean \pm SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. $^*P < 0.05$, $^{**}P < 0.01$, $^{***}P < 0.001$, compared with the LFCD group. $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, $^{\#\#\#}P < 0.001$, compared with the HFCD group.

Figure 4. FGF21 protects against HFCD-induced hepatic steatosis, inflammation and

fibrosis. (A) At week 23, liver weight was determined, and (B) scoring of histological features of steatosis, lobular inflammation and ballooning as well as (C) NAFLD activity was evaluated by H&E staining. (D) Liver fibrosis was assessed by Picrosirius Red (PSR) staining, and (E) hepatic hydroxyproline levels were determined. (F) Representative macroscopic, H&E and PSR pictures are shown. Data are shown as mean \pm SEM (n = 16-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey

678 post-test. $*P < 0.05$; $**P < 0.01$, $***P < 0.001$, compared with the LFCD group. $^{##}P < 0.01$;
679 $^{###}P < 0.001$, compared with the HFCD group.

680

681 **Figure 5. FGF21 abolishes liver lipotoxicity, accompanied by activation of hepatic**
682 **signaling involved in FA oxidation and cholesterol removal. (A)** Triglyceride (TG), total
683 cholesterol (TC) and phospholipid (PL) levels were determined in the liver (n = 18 per
684 group), and representative Oil Red O (ORO) pictures are shown. **(B)** The relative mRNA
685 expression of genes involved in fatty acid oxidation and **(C and D)** cholesterol removal (n =
686 15-18 per group) were determined in the liver. Data are shown as mean \pm SEM. Differences
687 were assessed using one-way ANOVA followed by a Tukey post-test. $**P < 0.01$, $***P <$
688 0.001 , compared with the LFCD group. $^{###}P < 0.001$, compared with the HFCD group.
689 *Abcg5*, ATP-binding cassette transporter G member 5; *Cpt1a*, carnitine palmitoyl
690 transferase 1 α ; *Cyp7a1*, cholesterol 7 α -hydroxylase; *Cyp8b1*, sterol 12 α -hydroxylase;
691 *Cyp27a1*, sterol 27-hydroxylase; *Pgc1a*, peroxisome proliferator-activated receptor gamma
692 coactivator 1 α ; *Ppara*, peroxisome proliferator-activated receptor α .

693

694 **Figure 6. FGF21 modulates hepatic macrophage pool and protects against COL1A1**
695 **accumulation, as predicted by the reduction of CD36^{hi} KCs and CD9^{hi} KCs. (A)** Uniform
696 manifold approximation and projection for dimension reduction (UMAP) of immune cell
697 subsets from livers after 23-week of intervention. **(B)** The number of resident KCs (ResKCs),
698 the proportion of CD11c⁺ ResKCs, and the expression of CD36 and CD9 in ResKCs were
699 quantified. **(C)** The amount of monocyte-derived KCs (MoKCs) was assessed, the
700 percentage of CD11c⁺ MoKCs was determined, the CD36 and CD9 expression levels in
701 MoKCs were quantified. **(D)** Hepatic inflammation was evaluated by pro-inflammatory gene
702 expression and the formation of CLSs within the liver. The mRNA expression of liver

fibrogenesis markers was quantified, and the protein expression of collagen type 1 α 1 (COL1A1) was determined. (E) The expression of CD36 in ResKCs, and the expression of CD9 and CD36 in MoKCs were plotted against COL1A1-positive area in the liver. (F) Mechanistic model. Data are shown as mean \pm SEM (A-B and E, n = 4-5 per group; D, n = 16-18 per group). Linear regression analyses were performed. Differences were assessed using one-way ANOVA followed by a Fisher's LSD test. * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the LFCD group. # P < 0.05, ## P < 0.01, ### P < 0.001, compared with the HFCD group. *Acta2*, actin α 2; *Ctgf*, connective tissue growth factor; FA, fatty acid; *Tgfb1*, transforming growth factor- β .

Figure supplements:

Figure 2-figure supplement 1. Liver-specific FGF21 overexpression tends to upregulate mRNA expression of FGF21 receptor 1 (FGFR1) and co-receptor β -Klotho (KLB) in white adipose tissue (WAT). The mRNA expression of KLB and FGFR1 in gonadal WAT (gWAT). Data are shown as mean \pm SEM (n = 16-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test.

Figure 3-figure supplement 1. HFCD increases fasting cholesterol levels. (A) Fasting plasma total cholesterol (TC) levels were measured over a 23-week intervention period (n = 14-18 per group), and (B) the distribution of the cholesterol over circulating lipoproteins was assessed at week 22 (pooled samples; n = 18 per group). Data are shown as mean \pm SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. *** P < 0.001, compared with the LFCD group. VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Figure 4-figure supplement 1. FGF21 abolishes HFCD-induced increase of hepatic lipid-positive area and the number of inflammatory foci. At week 23, (A) hepatic lipid droplet content and (B) inflammatory foci numbers were assessed by H&E staining. Data are shown as mean \pm SEM (n = 18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test. $**P < 0.01$, $***P < 0.001$, compared with the LFCD group. $^{\#}P < 0.01$ $^{###}P < 0.001$, compared with the HFCD group.

Figure 5-figure supplement 1. Liver-specific FGF21 overexpression upregulates hepatic mRNA expression of FGF21 receptors (FGFRs) and co-receptor β -Klotho (KLB). The mRNA levels of KLB and FGFRs in the liver. Data are shown as mean \pm SEM (n = 14-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, compared with the LFCD group. $^{\#}P < 0.01$, $^{###}P < 0.001$, compared with the HFCD group.

Figure 5-figure supplement 2. FGF21 increases apolipoprotein B mRNA (*Apob*) expression in the liver. At end of the study, hepatic expression of genes involved in (A) fatty acid uptake and (B) VLDL production was quantified (n = 15-18 per group). Data are shown as mean \pm SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. $***P < 0.001$, compared with the LFCD group. $^{###}P < 0.001$, compared with the HFCD group. *Apob*, apolipoprotein B; *Cd36*, cluster of differentiation 36; *Mttp*, microsomal triglyceride transfer protein.

Figure 6-figure supplement 1. FGF21 modulates the hepatic immune cell pool. (A) Flow cytometry gating strategy. (B) After 23 weeks of treatment, CD45⁺ cells were isolated from the liver, and the number of CD45⁺ cells, eosinophils, neutrophils, B cells, dendritic cells (DCs), T cells, natural killer (NK) cells, total Kupffer cells (KCs), Ly6C^{hi} monocytes and

monocyte-derived macrophages (MoDMacs) was assessed. Data are shown as mean \pm SEM (n = 4-5 per group). Differences were assessed using one-way ANOVA followed by a Fisher's LSD test. * P < 0.05, ** P < 0.01, compared with the LFCD group. # P < 0.05, ## P < 0.01, compared with the HFCD group.

Figure 6-figure supplement 2. CD36^{hi} ResKCs as well as CD36^{hi}/CD9^{hi} MoKCs positively correlate with NAFLD activity score and liver fibrosis. NAFLD activity scores and liver hydroxyproline levels were plotted against the expression of (A) CD9 and (B) CD36 in ResKCs as well as (C) CD9 and (D) CD36 in MoKCs. (E) Hepatic expression of collagen type 1 α 1 (COL1A1) was plotted against the expression of CD9 in ResKCs. Linear regression analyses were performed. Data are represented as mean \pm SEM (n = 5 per group).

List of Supplementary Files:

Supplementary File 1: Supporting Materials and Methods.





Figure 1






Figure 3





Figure 4






Figure 6




Figure 2-figure supplement 1




Figure 3-figure supplement 1




Figure 4 Figure supplement 1




Figure 5-figure supplement 1




Figure 5-figure supplement 2

